AI assistant
Sending…
GALECTIN THERAPEUTICS INC — Director's Dealing 2013
Jul 8, 2013
33422_dirs_2013-07-08_cec5250e-0b8e-487b-b5eb-1ab700d92176.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2013-07-03
Reporting Person: MAULDIN JOHN F (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2013-07-03 | Common Stock | P | 876 | $4.2337 | Acquired | 14352 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 4947 | Indirect |
Footnotes
F1: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2013.
F2: Reflects weighted average price. Range of prices were between $4.22 and $4.25. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
More from GALECTIN THERAPEUTICS INC
Regulatory Filings
2026
May 15
Interim / Quarterly Report
2026
May 15
Capital/Financing Update
2026
Mar 31
Earnings Release
2026
Mar 31
Annual Report
2026
Mar 31
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Board/Management Information
2026
Mar 17
Director's Dealing
2026
Feb 9
Board/Management Information
2026
Jan 21